Stoke Therapeutics (STOK) said Tuesday that Edward Kaye is stepping down as chief executive, effective Wednesday.
The company said Kaye would continue to serve as an adviser to the company and remain a director of its board.
Ian Smith, currently a senior adviser to Bain Capital Life Sciences, has been named interim CEO.
Arthur Tzianabos, Stoke's board chairman, will also take on the role of interim executive chairman, supporting the transition and leading the search for a permanent CEO.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.